Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Oncopeptides AB ( (SE:ONCO) ) has shared an announcement.
Oncopeptides AB reported a significant growth in net sales for Q3 2025, with a 174% increase year over year, driven by its key European markets. The company is progressing towards becoming cash flow positive by the end of 2026 and is in negotiations with potential partners in Japan. The period also saw the oversubscription of a rights issue and the inclusion of their drug Pepaxti in European guidelines, which could enhance their market positioning and stakeholder confidence.
The most recent analyst rating on (SE:ONCO) stock is a Hold with a SEK5.50 price target. To see the full list of analyst forecasts on Oncopeptides AB stock, see the SE:ONCO Stock Forecast page.
More about Oncopeptides AB
Oncopeptides AB is a biotechnology company based in Stockholm, Sweden, focusing on developing treatments for difficult-to-treat cancers. The company is listed on Nasdaq Stockholm and is known for its drug Pepaxti, which is used in the treatment of multiple myeloma and has been included in European treatment guidelines.
Average Trading Volume: 3,923,134
Technical Sentiment Signal: Hold
Current Market Cap: SEK1.48B
Find detailed analytics on ONCO stock on TipRanks’ Stock Analysis page.